JP2023514332A - 多糖－タンパク質コンジュゲートを含むａ群ｓｔｒｅｐ免疫原性組成物 - Google Patents

多糖－タンパク質コンジュゲートを含むａ群ｓｔｒｅｐ免疫原性組成物 Download PDF

Info

Publication number
JP2023514332A
JP2023514332A JP2022549495A JP2022549495A JP2023514332A JP 2023514332 A JP2023514332 A JP 2023514332A JP 2022549495 A JP2022549495 A JP 2022549495A JP 2022549495 A JP2022549495 A JP 2022549495A JP 2023514332 A JP2023514332 A JP 2023514332A
Authority
JP
Japan
Prior art keywords
seq
polypeptide
immunogenic composition
gas
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022549495A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023514332A5 (cg-RX-API-DMAC7.html
Inventor
シー フェアマン，ジェファリー
カプール，ニーラジ
ティ デイビー，ピーター
エイ セドラ，アンジー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vaxcyte Inc
Original Assignee
Vaxcyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxcyte Inc filed Critical Vaxcyte Inc
Publication of JP2023514332A publication Critical patent/JP2023514332A/ja
Publication of JP2023514332A5 publication Critical patent/JP2023514332A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/2111—C5a peptidase (3.4.21.110)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2022549495A 2020-02-18 2021-02-17 多糖－タンパク質コンジュゲートを含むａ群ｓｔｒｅｐ免疫原性組成物 Pending JP2023514332A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202062977886P 2020-02-18 2020-02-18
US62/977,886 2020-02-18
US202063013924P 2020-04-22 2020-04-22
US63/013,924 2020-04-22
US202063090069P 2020-10-09 2020-10-09
US63/090,069 2020-10-09
US202063123293P 2020-12-09 2020-12-09
US63/123,293 2020-12-09
PCT/US2021/018402 WO2021167996A1 (en) 2020-02-18 2021-02-17 Group a strep immunogenic compositions with polysaccharide-protein conjugates

Publications (2)

Publication Number Publication Date
JP2023514332A true JP2023514332A (ja) 2023-04-05
JP2023514332A5 JP2023514332A5 (cg-RX-API-DMAC7.html) 2024-02-27

Family

ID=74860575

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022549495A Pending JP2023514332A (ja) 2020-02-18 2021-02-17 多糖－タンパク質コンジュゲートを含むａ群ｓｔｒｅｐ免疫原性組成物

Country Status (13)

Country Link
US (1) US20230293658A1 (cg-RX-API-DMAC7.html)
EP (1) EP4106807A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023514332A (cg-RX-API-DMAC7.html)
KR (1) KR20220143107A (cg-RX-API-DMAC7.html)
CN (1) CN115175697A (cg-RX-API-DMAC7.html)
AU (1) AU2021224585A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022016268A2 (cg-RX-API-DMAC7.html)
CA (1) CA3168201A1 (cg-RX-API-DMAC7.html)
IL (1) IL295702A (cg-RX-API-DMAC7.html)
MX (1) MX2022010129A (cg-RX-API-DMAC7.html)
PH (1) PH12022552118A1 (cg-RX-API-DMAC7.html)
TW (1) TW202136285A (cg-RX-API-DMAC7.html)
WO (1) WO2021167996A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023538365A (ja) 2020-08-19 2023-09-07 バックスサイト・インコーポレイテッド 担体－タンパク質多糖結合方法
JP2024506713A (ja) * 2021-02-17 2024-02-14 バックスサイト・インコーポレイテッド 多糖およびそのポリペプチドコンジュゲートの精製方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013020090A2 (en) * 2011-08-04 2013-02-07 The Regents Of The University Of California STREPTOCOCCAL GLcNAc-LACKING GLYCOPOLYPEPTIDES, CELL WALL CARBOHYDRATES, STREPTOCOCCUS VACCINES, AND METHODS FOR MAKING AND USING THEM
WO2018126229A2 (en) * 2016-12-30 2018-07-05 Sutrovax, Inc. Polypeptide-antigen conjugates with non-natural amino acids

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355255B1 (en) * 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
NZ586430A (en) * 2007-12-21 2012-09-28 Novartis Ag Mutant forms of streptolysin o (slo)
PT2349520T (pt) 2008-10-27 2016-08-16 Glaxosmithkline Biologicals Sa Método de purificação para hidrato de carbono de estreptococos grupo a
AU2013320313B2 (en) * 2012-09-18 2018-07-12 Glaxosmithkline Biologicals Sa Outer membrane vesicles

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013020090A2 (en) * 2011-08-04 2013-02-07 The Regents Of The University Of California STREPTOCOCCAL GLcNAc-LACKING GLYCOPOLYPEPTIDES, CELL WALL CARBOHYDRATES, STREPTOCOCCUS VACCINES, AND METHODS FOR MAKING AND USING THEM
WO2018126229A2 (en) * 2016-12-30 2018-07-05 Sutrovax, Inc. Polypeptide-antigen conjugates with non-natural amino acids

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ACS INFECT. DIS., vol. 6, JPN6025008748, 2019, pages 281 - 290, ISSN: 0005542828 *
CELL HOST MICROBE, vol. 15, JPN6025008749, 2014, pages 729 - 740, ISSN: 0005542830 *
MBIO, vol. Vol.10 Iss.2, JPN6025008750, 2019, ISSN: 0005542829 *

Also Published As

Publication number Publication date
MX2022010129A (es) 2022-09-05
TW202136285A (zh) 2021-10-01
CN115175697A (zh) 2022-10-11
IL295702A (en) 2022-10-01
AU2021224585A1 (en) 2022-10-13
PH12022552118A1 (en) 2024-01-29
EP4106807A1 (en) 2022-12-28
WO2021167996A1 (en) 2021-08-26
US20230293658A1 (en) 2023-09-21
KR20220143107A (ko) 2022-10-24
BR112022016268A2 (pt) 2022-10-11
CA3168201A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
US20240358823A1 (en) Conjugated vaccine carrier proteins
CA2566344C (en) Mutant pneumolysin proteins
AU2021208493B2 (en) FimH mutant, compositions therewith and use thereof
US20240000926A1 (en) Purification processes for polysaccharides and polypeptide conjugates thereof
US20230293658A1 (en) Group a strep immunogenic compositions with polysaccharide-protein conjugates
CN113173977B (zh) 一种双功能抗原、其制备方法及应用
WO2005108419A1 (en) Mutant cholesterol-binding cytolysin proteins
JP2024109576A (ja) ＦｉｍＨ変異体、それを含む組成物、及びその使用
US8338137B2 (en) Type 5 and type 8 capsular polysaccharides of overproducing S. aureus strains
Shivachandra et al. Immunogenicity of recombinant Omp16 protein of Pasteurella multocida B: 2 in mouse model
US8916162B2 (en) Botulinum neurotoxin antigenic compositions and methods
Skwarczynski et al. Group A streptococcal vaccine candidates based on the conserved conformational epitope from M protein
JP2018522978A (ja) 免疫原性組成物
Lee et al. Antigenicity of partial fragments of recombinant Pasteurella multocida toxin.
Burns Development of a Glycoconjugate Vaccine Against Group A Streptococcus (GAS)
CN117479961A (zh) 多糖及其多肽缀合物的纯化方法
AU2023377159A1 (en) Group a streptococcus vaccine antigen
US8420090B2 (en) Recombinant B. pseudomallei adhesin protein and methods and uses thereof
HK40012911A (zh) 克雷伯氏肺炎杆菌的荚膜多醣疫苗

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250604

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251007

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260729